Company intelligence / Profile preview

XOMA

Emeryville, California, United Statesxoma.com ↗

Ownership: Public · XOMA
Development stage: Other

Overview

XOMA has built a diversified portfolio of over 120 milestone and royalty assets licensed to third-party biotech and pharma companies. The company receives milestone payments as partnered programs advance through clinical development and commercialization. Recent highlights include significant milestones from Novartis for NIS793 entering Phase III trials and the acquisition of additional economics in late-stage assets like mezagitamab[6][7]. In recent years, two partner NDAs were submitted to the FDA; commercial royalties are being received on marketed products such as VABYSMO® and DSUVIA®[8].

Therapeutic areas: Women's HealthRare DiseasesOncologyOther
Modalities: Monoclonal antibodySmall moleculeBiologic
Industry: Investors

Partnerships

Novartis (NIS793)Takeda/BioInvent International AB (mezagitamab)Roche/Genentech (VABYSMO®)Zevra Therapeutics

Beyond the preview

Go deeper on XOMA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XOMA.